Treatment for acute myelogenous leukemia by low dose Total Body Irradiation (TBI) based conditioning and hematopoietic cell transplantation from related and unrelated donors
Georg‐Nikolaus Franke(University Hospital Leipzig), Rainer Storb(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), David G. Maloney(Fred Hutch Cancer Center), Monic J. Stuart(United States Department of Veterans Affairs), Benedetto Bruno(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Haifa Kathrin Al‐Ali(University Hospital in Halle), Elliot Epner(Fred Hutch Cancer Center), H. Greinix(Medical University of Vienna), Thoralf Lange, Effie W. Petersdorf(University of Washington), Leanthe Grommisch(Leipzig University), Barry E. Storer(City Of Hope National Medical Center), Aloïs Gratwohl, Ute Hegenbart(Heidelberg University), D Niederwieser(University Hospital of Basel), Richard T. Maziarz(Oregon Health & Science University), Brenda M. Sandmaier(University of Washington), Peter A. McSweeney(Mesoblast (United States)), E.D. Agura, Finn Bo Petersen(Intermountain Healthcare), Bernard Rio(Hotel Dieu Hospital), Michael B. Maris(Colorado Blood Cancer Institute), T Chauncey, Wolfram Poenisch(Leipzig University), C. Cordonnier(Centre Hospitalier Universitaire Amiens-Picardie), Judith A. Shizuru(Stanford University)
Cited by 8
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k